Publications

Adam Brufsky, MD, PhD

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. PubMed PMID: 31157962.
Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, Stearns V. Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2- Advanced Breast Cancer Enrolled in an Expanded Access Program. Clin Breast Cancer. 2019 Apr 18; doi: 10.1016/j.clbc.2019.04.005. PubMed PMID: 31104984.
Sambade MJ, Prince G, Deal AM, Trembath D, McKee M, Garrett A, Keith K, Ramirez J, Midkiff B, Blackwell K, Sammons S, Leone JP, Brufsky A, Morikawa A, Brogi E, Seidman A, Ewend M, Carey LA, Moschos SJ, Hamilton RL, Vincent B, Anders C. Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. Breast Cancer Res Treat. 2019 Jul;176(2):321-328. doi: 10.1007/s10549-019-05211-1. PubMed PMID: 31016641.
Jiang X, Wells A, Brufsky A, Neapolitan R. A clinical decision support system learned from data to personalize treatment recommendations towards preventing breast cancer metastasis. PLoS One. 2019;14(3):e0213292. doi: 10.1371/journal.pone.0213292. PubMed PMID: 30849111; PMCID: PMC6407919.
Klar N, Rosenzweig M, Diergaarde B, Brufsky A. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer. Clin Breast Cancer. 2019 Feb 6; doi: 10.1016/j.clbc.2019.01.014. PubMed PMID: 30827763.
Smith NG, Gyanchandani R, Shah OS, Gurda GT, Lucas PC, Hartmaier RJ, Brufsky AM, Puhalla S, Bahreini A, Kota K, Wald AI, Nikiforov YE, Nikiforova MN, Oesterreich S, Lee AV. Targeted mutation detection in breast cancer using MammaSeq™. Breast Cancer Res. 2019 Feb 8;21(1):22. doi: 10.1186/s13058-019-1102-7. PubMed PMID: 30736836; PMCID: PMC6368740.
Han M, Salamat A, Zhu L, Zhang H, Clark BZ, Dabbs DJ, Carter GJ, Brufsky AM, Jankowitz RC, Puhalla SL, Johnson RR, Soran A, Steiman JG, McAuliffe PF, Diego EJ, Bhargava R. Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy. Mod Pathol. 2019 Jun;32(6):807-816. doi: 10.1038/s41379-019-0208-x. PubMed PMID: 30723293.
Klar N, Brufsky A. Extended adjuvant therapy for early-stage breast cancer: Are there markers for its use? Breast J. 2019 Jan;25(1):7-8. doi: 10.1111/tbj.13038. PubMed PMID: 30659735.
Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 Apr 15;25(8):2433-2441. doi: 10.1158/1078-0432.CCR-18-2366. PubMed PMID: 30593513.
Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):88-99. doi: 10.1016/S1470-2045(18)30621-1. PubMed PMID: 30509771.
Gyanchandani R, Kvam E, Heller R, Finehout E, Smith N, Kota K, Nelson JR, Griffin W, Puhalla S, Brufsky AM, Davidson NE, Lee AV. Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. Sci Rep. 2018 Nov 23;8(1):17313. doi: 10.1038/s41598-018-35470-9. PubMed PMID: 30470782; PMCID: PMC6251935.
Beckwitt CH, Brufsky A, Oltvai ZN, Wells A. Statin drugs to reduce breast cancer recurrence and mortality. Breast Cancer Res. 2018 Nov 20;20(1):144. doi: 10.1186/s13058-018-1066-z. PubMed PMID: 30458856; PMCID: PMC6247616.
Heng YJ, Wang J, Ahearn TU, Brown SB, Zhang X, Ambrosone CB, de Andrade VP, Brufsky AM, Couch FJ, King TA, Modugno F, Vachon CM, DuPre NC, Garcia-Closas M, Troester MA, Hunter DJ, Eliassen AH, Tamimi RM, Hankinson SE, Beck AH. Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. Breast Cancer Res Treat. 2019 Feb;173(3):667-677. doi: 10.1007/s10549-018-5034-1. PubMed PMID: 30387004; PMCID: PMC6391202.
Pandey A, Brufsky AM. Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use. Clin Breast Cancer. 2019 Feb;19(1):e7-e11. doi: 10.1016/j.clbc.2018.09.010. PubMed PMID: 30391215.
Bortsov AV, Devor M, Kaunisto MA, Kalso E, Brufsky A, Kehlet H, Aasvang E, Bittner R, Diatchenko L, Belfer I. CACNG2 polymorphisms associate with chronic pain after mastectomy. Pain. 2019 Mar;160(3):561-568. doi: 10.1097/j.pain.0000000000001432. PubMed PMID: 30371558; PMCID: PMC6377334.
Basudan A, Priedigkeit N, Hartmaier RJ, Sokol ES, Bahreini A, Watters RJ, Boisen MM, Bhargava R, Weiss KR, Karsten MM, Denkert C, Blohmer JU, Leone JP, Hamilton RL, Brufsky AM, Elishaev E, Lucas PC, Lee AV, Oesterreich S. Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Mol Cancer Res. 2019 Feb;17(2):457-468. doi: 10.1158/1541-7786.MCR-18-0946. PubMed PMID: 30355675; PMCID: PMC6359977.
Merriman JD, Sereika SM, Conley YP, Koleck TA, Zhu Y, Phillips ML, Bertocci MA, Brufsky AM, Bender CM. Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer. Biol Res Nurs. 2019 Jan;21(1):50-60. doi: 10.1177/1099800418799964. PubMed PMID: 30213196.
Stearns V, Brufsky AM, Verma S, Cotter MJ, Lu DR, Dequen F, Joy AA. Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Clin Breast Cancer. 2018 Dec;18(6):e1239-e1245. doi: 10.1016/j.clbc.2018.07.007. PubMed PMID: 30172722.
Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol. 2018 Sep 1;36(25):2621-2629. doi: 10.1200/JCO.2018.79.2028. PubMed PMID: 30040523; PMCID: PMC6118403.
Varešlija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O'Halloran PJ, Ward E, Cocchiglia S, Hartmaier R, Castro CA, Zhu L, Tseng GC, Lucas PC, Puhalla SL, Brufsky AM, Hamilton RL, Mathew A, Leone JP, Basudan A, Hudson L, Dwyer R, Das S, O'Connor DP, Buckley PG, Farrell M, Hill ADK, Oesterreich S, Lee AV, Young LS. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. J Natl Cancer Inst. 2019 Apr 1;111(4):388-398. doi: 10.1093/jnci/djy110. PubMed PMID: 29961873; PMCID: PMC6449168.
Dabbs DJ, Clark BZ, Serdy K, Onisko A, Brufsky AM, Smalley S, Perkins S, Bhargava R. Pathologist's health-care value in the triage of Oncotype DX® testing: a value-based pathology study of tumour biology with outcomes. Histopathology. 2018 Oct;73(4):692-700. doi: 10.1111/his.13690. PubMed PMID: 29920746.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. PubMed PMID: 29860917; PMCID: PMC6172658.
Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R. Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease? Am J Clin Pathol. 2018 May 31;150(1):34-42. doi: 10.1093/ajcp/aqy028. PubMed PMID: 29741562.
Bender CM, Merriman JD, Sereika SM, Gentry AL, Casillo FE, Koleck TA, Rosenzweig MQ, Brufsky AM, McAuliffe P, Zhu Y, Conley YP. Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer. Oncol Nurs Forum. 2018 May 1;45(3):308-326. doi: 10.1188/18.ONF.308-326. PubMed PMID: 29683114; PMCID: PMC6052441.
Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, Cheema P, Truica CI, Wolff AC, Soori GS, Haley B, Wassenaar TR, Goldstein LJ, Miller KD, Sparano JA. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. J Clin Oncol. 2018 Jun 1;36(16):1556-1563. doi: 10.1200/JCO.2017.76.9331. PubMed PMID: 29664714.
Clark BZ, Farrugia DJ, Landmann A, Diego EJ, Dabbs DJ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R. Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer. Am J Clin Pathol. 2018 Mar 7;149(4):332-343. doi: 10.1093/ajcp/aqx168. PubMed PMID: 29481634.
Belfer I, Pollock NI, Martin JL, Lim KG, De La Cruz C, Van Londen G, Nunziato-Virga SR, Stranieri K, Brufsky AM, Wang H. Effect of gastroretentive gabapentin (Gralise) on postmastectomy pain syndrome: a proof-of-principle open-label study. Pain Rep. 2017 May;2(3):e596. doi: 10.1097/PR9.0000000000000596. PubMed PMID: 29392212; PMCID: PMC5741302.
Brufsky AM, Dickler MN. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. Oncologist. 2018 May;23(5):528-539. doi: 10.1634/theoncologist.2017-0423. PubMed PMID: 29352052; PMCID: PMC5947450.
Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. J Clin Oncol. 2017 Dec 10;35(35):3942-3948. doi: 10.1200/JCO.2017.74.1165. PubMed PMID: 29072977; PMCID: PMC5721228.
Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018 Feb 1;110(2): doi: 10.1093/jnci/djx162. PubMed PMID: 28954297; PMCID: PMC5825682.
Kota K, Brufsky A, Oesterreich S, Lee A. Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification. Cureus. 2017 Jul 6;9(7):e1434. doi: 10.7759/cureus.1434. PubMed PMID: 28924522; PMCID: PMC5587405.
Wang J, Heng YJ, Eliassen AH, Tamimi RM, Hazra A, Carey VJ, Ambrosone CB, de Andrade VP, Brufsky A, Couch FJ, King TA, Modugno F, Vachon CM, Hunter DJ, Beck AH, Hankinson SE. Alcohol consumption and breast tumor gene expression. Breast Cancer Res. 2017 Sep 12;19(1):108. doi: 10.1186/s13058-017-0901-y. PubMed PMID: 28899409; PMCID: PMC5596493.
Priedigkeit N, Watters RJ, Lucas PC, Basudan A, Bhargava R, Horne W, Kolls JK, Fang Z, Rosenzweig MQ, Brufsky AM, Weiss KR, Oesterreich S, Lee AV. Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI Insight. 2017 Sep 7;2(17): doi: 10.1172/jci.insight.95703. PubMed PMID: 28878133; PMCID: PMC5621874.
Mathew A, Achkar T, Abberbock S, Sandhu GS, Jacob ME, Villgran VD, Rosenzweig MQ, Puhalla S, Brufsky AM. Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. Breast J. 2017 Nov;23(6):718-722. doi: 10.1111/tbj.12905. PubMed PMID: 28845536; PMCID: PMC5675818.
Schroeder B, Zhang Y, Stål O, Fornander T, Brufsky A, Sgroi DC, Schnabel CA. Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer. NPJ Breast Cancer. 2017;328. doi: 10.1038/s41523-017-0037-3. PubMed PMID: 28795152; PMCID: PMC5543049.
Mathew A, Rajagopal PS, Villgran V, Sandhu GS, Jankowitz RC, Jacob M, Rosenzweig M, Oesterreich S, Brufsky A. Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast. Geburtshilfe Frauenheilkd. 2017 Jun;77(6):660-666. doi: 10.1055/s-0043-109374. PubMed PMID: 28757653; PMCID: PMC5489406.
Brufsky AM. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev. 2017 Sep;5922-32. doi: 10.1016/j.ctrv.2017.06.004. PubMed PMID: 28719836.
Mathew A, Brufsky A. TACT2: improving treatment tolerability in early breast cancer. Lancet Oncol. 2017 Jul;18(7):843-845. doi: 10.1016/S1470-2045(17)30437-0. PubMed PMID: 28677561.
Farrugia DJ, Landmann A, Zhu L, Diego EJ, Johnson RR, Bonaventura M, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Lembersky BC, Ahrendt GM, McAuliffe PF, Bhargava R. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol. 2017 Aug;30(8):1078-1085. doi: 10.1038/modpathol.2017.41. PubMed PMID: 28548119.
Yardley DA, Arrowsmith ER, Daniel BR, Eakle J, Brufsky A, Drosick DR, Kudrik F, Bosserman LD, Keaton MR, Goble SA, Bubis JA, Priego VM, Pendergrass K, Manalo Y, Bury M, Gravenor DS, Rodriguez GI, Inhorn RC, Young RR, Harwin WN, Silver C, Hainsworth JD, Burris HA 3rd. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2017 Aug;164(3):649-658. doi: 10.1007/s10549-017-4285-6. PubMed PMID: 28508185.
Koleck TA, Bender CM, Clark BZ, Ryan CM, Ghotkar P, Brufsky A, McAuliffe PF, Rastogi P, Sereika SM, Conley YP. An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors. Breast Cancer (Dove Med Press). 2017;995-110. doi: 10.2147/BCTT.S123785. PubMed PMID: 28424560; PMCID: PMC5344452.
Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017 Aug 10;35(23):2647-2655. doi: 10.1200/JCO.2016.71.4147. PubMed PMID: 28398846; PMCID: PMC5549453.
Brufsky A. nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings. Exp Hematol Oncol. 2017;67. doi: 10.1186/s40164-017-0066-5. PubMed PMID: 28344858; PMCID: PMC5361712.
Mathew A, Brufsky A. Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer. Lancet Oncol. 2017 Apr;18(4):428-429. doi: 10.1016/S1470-2045(17)30150-X. PubMed PMID: 28238596.
Yee MK, Sereika SM, Bender CM, Brufsky AM, Connolly MC, Rosenzweig MQ. Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer. Cancer. 2017 Jun 1;123(11):2061-2069. doi: 10.1002/cncr.30575. PubMed PMID: 28199006.
Koleck TA, Bender CM, Sereika SM, Ryan CM, Ghotkar P, Brufsky AM, Jankowitz RC, McAuliffe PF, Clark BZ, Conley YP. Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer. Cancer Med. 2017 Feb;6(2):339-348. doi: 10.1002/cam4.964. PubMed PMID: 28083945; PMCID: PMC5313647.
Puhalla S, Wilks S, Brufsky AM, O'Shaughnessy J, Schwartzberg LS, Berrak E, Song J, Vahdat L. Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study. Breast Cancer (Dove Med Press). 2016;8231-239. doi: 10.2147/BCTT.S98696. PubMed PMID: 27994483; PMCID: PMC5153255.
Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res. 2017 Jun 1;23(11):2691-2701. doi: 10.1158/1078-0432.CCR-16-1729. PubMed PMID: 27979916; PMCID: PMC5457329.
Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, Brufsky AM, Young L, Lee AV. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncol. 2017 May 1;3(5):666-671. doi: 10.1001/jamaoncol.2016.5630. PubMed PMID: 27926948; PMCID: PMC5508875.
Bear HD, Tang G, Rastogi P, Geyer CE Jr, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Ann Surg Oncol. 2017 Jul;24(7):1853-1860. doi: 10.1245/s10434-016-5662-9. PubMed PMID: 27864694; PMCID: PMC5821429.
Gyanchandani R, Lin Y, Lin HM, Cooper K, Normolle DP, Brufsky A, Fastuca M, Crosson W, Oesterreich S, Davidson NE, Bhargava R, Dabbs DJ, Lee AV. Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. Clin Cancer Res. 2016 Nov 1;22(21):5362-5369. doi: 10.1158/1078-0432.CCR-15-2889. PubMed PMID: 27185370; PMCID: PMC5093028.
Brufsky AM, Ormerod C, Bell Dickson R, Citron ML. Understanding the Needs of Patients with Metastatic Breast Cancer: Results of the Make Your Dialogue Count Survey. Breast J. 2017 Jan;23(1):17-25. doi: 10.1111/tbj.12675. PubMed PMID: 27623209.
Yardley DA, Reeves J, Dees EC, Osborne C, Paul D, Ademuyiwa F, Soliman H, Guthrie T, Andersen J, Krekow L, Choksi J, Daniel B, Danso M, Favret A, Oommen S, Brufsky A, Bromund JL, Lin Y, Ibrahim AB, Richards PD. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clin Breast Cancer. 2016 Dec;16(6):471-479.e1. doi: 10.1016/j.clbc.2016.07.005. PubMed PMID: 27569274.
Sgroi DC, Brufsky A. Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions. J Clin Oncol. 2016 Nov 10;34(32):3941-3942. doi: 10.1200/JCO.2016.67.2949. PubMed PMID: 27551134.
Gyanchandani R, Kota KJ, Jonnalagadda AR, Minteer T, Knapick BA, Oesterreich S, Brufsky AM, Lee AV, Puhalla SL. Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. Oncotarget. 2017 Sep 15;8(40):66901-66911. doi: 10.18632/oncotarget.11383. PubMed PMID: 28978004; PMCID: PMC5620144.
Brufsky AM, Davidson NE. Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation? Clin Cancer Res. 2016 Oct 15;22(20):4963-4965. doi: 10.1158/1078-0432.CCR-16-1513. PubMed PMID: 27521446; PMCID: PMC5154749.
Brufsky A. Is there room for bevacizumab in metastatic breast cancer? Lancet Oncol. 2016 Sep;17(9):1175-6. doi: 10.1016/S1470-2045(16)30295-9. PubMed PMID: 27501769.
Ellis PG, Brufsky AM, Beriwal S, Lokay KG, Benson HO, McCutcheon SB, Krebs M. Pathways Clinical Decision Support for Appropriate Use of Key Biomarkers. J Oncol Pract. 2016 Jun;12(6):e681-7. doi: 10.1200/JOP.2015.010546. PubMed PMID: 27221995.
Koleck TA, Bender CM, Sereika SM, Brufsky AM, Lembersky BC, McAuliffe PF, Puhalla SL, Rastogi P, Conley YP. Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study. Springerplus. 2016;5422. doi: 10.1186/s40064-016-2061-4. PubMed PMID: 27099827; PMCID: PMC4826652.
Prasad C, Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial. Bone. 2016 Sep;90123-6. doi: 10.1016/j.bone.2016.03.010. PubMed PMID: 27018037.
Jiang Y, Sereika SM, Bender CM, Brufsky AM, Rosenzweig MQ. Beliefs in Chemotherapy and Knowledge of Cancer and Treatment Among African American Women With Newly Diagnosed Breast Cancer. Oncol Nurs Forum. 2016 Mar;43(2):180-9. doi: 10.1188/16.ONF.180-189. PubMed PMID: 26906129.
Gurda GT, Ambros T, Nikiforova MN, Nikiforov YE, Lucas PC, Dabbs DJ, Lee AV, Brufsky AM, Puhalla SL, Bhargava R. Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer. Appl Immunohistochem Mol Morphol. 2017 Jul;25(6):392-398. doi: 10.1097/PAI.0000000000000322. PubMed PMID: 26862949.
Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2016 Feb 3;1763. doi: 10.1186/s13063-016-1195-6. PubMed PMID: 26841937; PMCID: PMC4739389.
Brufsky AM. Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clin Med Insights Oncol. 2015;9137-47. doi: 10.4137/CMO.S31586. PubMed PMID: 26793013; PMCID: PMC4697769.
Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016 Feb 27;387(10021):857-65. doi: 10.1016/S0140-6736(15)01169-1. PubMed PMID: 26686960; PMCID: PMC4792658.
Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016 Feb 27;387(10021):849-56. doi: 10.1016/S0140-6736(15)01168-X. PubMed PMID: 26686957; PMCID: PMC4792688.
Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2015 Dec 16;16575. doi: 10.1186/s13063-015-1101-7. PubMed PMID: 26673577; PMCID: PMC4682258.
Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF, Weiss KR, Mathew A, Leone JP, Davidson NE, Nikiforova MN, Brufsky AM, Ambros TF, Stern AM, Puhalla SL, Lee AV, Oesterreich S. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clin Cancer Res. 2016 Mar 1;22(5):1130-7. doi: 10.1158/1078-0432.CCR-15-1534. PubMed PMID: 26500237; PMCID: PMC4775406.
Merriman JD, Sereika SM, Brufsky AM, McAuliffe PF, McGuire KP, Myers JS, Phillips ML, Ryan CM, Gentry AL, Jones LD, Bender CM. Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. Psychooncology. 2017 Jan;26(1):44-52. doi: 10.1002/pon.4009. PubMed PMID: 26486371; PMCID: PMC4969219.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. PubMed PMID: 26412349; PMCID: PMC4701034.
Brown DD, Dabbs DJ, Lee AV, McGuire KP, Ahrendt GM, Bhargava R, Davidson NE, Brufsky AM, Johnson RR, Oesterreich S, McAuliffe PF. Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. Breast Cancer Res Treat. 2015 Sep;153(2):311-21. doi: 10.1007/s10549-015-3551-8. PubMed PMID: 26283301.
Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1037-1048. doi: 10.1016/S1470-2045(15)00041-8. PubMed PMID: 26272770; PMCID: PMC4624323.
Brufsky A, Mathew A. Bisphosphonates, bone, and breast cancer recurrence. Lancet. 2015 Oct 3;386(10001):1319-1320. doi: 10.1016/S0140-6736(15)61163-1. PubMed PMID: 26211825.
Leone JP, Bhargava R, Theisen BK, Hamilton RL, Lee AV, Brufsky AM. Expression of high affinity folate receptor in breast cancer brain metastasis. Oncotarget. 2015 Oct 6;6(30):30327-33. doi: 10.18632/oncotarget.4639. PubMed PMID: 26160847; PMCID: PMC4745802.
Bender CM, Merriman JD, Gentry AL, Ahrendt GM, Berga SL, Brufsky AM, Casillo FE, Dailey MM, Erickson KI, Kratofil FM, McAuliffe PF, Rosenzweig MQ, Ryan CM, Sereika SM. Patterns of change in cognitive function with anastrozole therapy. Cancer. 2015 Aug 1;121(15):2627-36. doi: 10.1002/cncr.29393. PubMed PMID: 25906766; PMCID: PMC4512875.
Leone JP, Lee AV, Brufsky AM. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Med. 2015 Jul;4(7):989-94. doi: 10.1002/cam4.439. PubMed PMID: 25756607; PMCID: PMC4529337.
Mathew A, Brufsky AM. The use of adjuvant bisphophonates in the treatment of early-stage breast cancer. Clin Adv Hematol Oncol. 2014 Nov;12(11):749-56. PubMed PMID: 25674714.
Mathew A, Brufsky AM, Davidson NE. Can circulating tumor cells predict resistance in metastatic breast cancer? Clin Cancer Res. 2015 Jun 1;21(11):2421-3. doi: 10.1158/1078-0432.CCR-14-2967. PubMed PMID: 25645864; PMCID: PMC4694574.
Brufsky A. Length of chemotherapy and use of bevacizumab for breast cancer. Lancet Oncol. 2014 Nov;15(12):1285-7. doi: 10.1016/S1470-2045(14)70480-2. PubMed PMID: 25439683.
Mathew A, Brufsky A. Breast cancer: Zoledronic acid--more than just a bone drug. Nat Rev Clin Oncol. 2014 Oct;11(10):564-5. doi: 10.1038/nrclinonc.2014.152. PubMed PMID: 25200411.
Brufsky AM. Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. Breast Cancer (Auckl). 2014;8109-18. doi: 10.4137/BCBCR.S9453. PubMed PMID: 25125981; PMCID: PMC4125367.
Brufsky AM. Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer. Am J Clin Oncol. 2014 Aug;37(4):404-10. doi: 10.1097/COC.0000000000000086. PubMed PMID: 24853663; PMCID: PMC4162320.

<< Investigators Search

Top